A retrospective cohort study of bebtelovimab comparable to ritonavir-boosted nirmatrelvir in patients with coronavirus disease-2019
Latest Information Update: 23 Sep 2022
At a glance
- Drugs Bebtelovimab (Primary) ; Nirmatrelvir+ritonavir (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 23 Sep 2022 New trial record
- 17 Sep 2022 Results published in the Journal of Infectious Diseases